Gabapentin Capsule
Product Images NDC 68788-8563

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 68788-8563). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Gabapentin Capsules 100mg Cv (Gabapentin 100mg 100s)

Label for Gabapentin Capsules 100 mg by Preferred Pharmaceuticals Inc. The label indicates the product is generic for Neurontin, with each capsule containing 100 mg of Gabapentin. It includes storage instructions, manufacturer information (ScieGen Pharmaceuticals, Inc), and bilingual dosage directions in English and Spanish. The label is designed for prescription use with typical batch, lot, and NDC fields present but not filled in.*

FDA Label Image

Figure 1 (Image 01)

A line chart showing mean pain score over an 8-week period comparing placebo and Gabapentin 3600 mg/day. The x-axis represents weeks from baseline to week 8, and the y-axis shows mean pain score from 0 to 10. The chart indicates a 4-week dose titration period followed by a 4-week fixed dose period, with Gabapentin showing a greater decrease in mean pain score than placebo over time.*

FDA Label Image

Figure 2 (Image 02)

Line graph depicting mean pain scores over 7 weeks, comparing placebo and gabapentin at 1800 mg/day and 2400 mg/day doses. The x-axis represents weeks including baseline, the y-axis shows mean pain score from 0 to 10. The study includes a 3-week dose titration period followed by a 4-week fixed dose period.*

FDA Label Image

Figure 3 (Image 03)

A bar chart titled 'Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies' comparing placebo (PBO) and gabapentin (GBP) doses in two studies. Study 1 shows PBO at 12% and GBP 3600 mg at 29%. Study 2 shows PBO at 14%, GBP 1800 mg at 32%, and GBP 2400 mg at 34%. Statistical significance is noted with p-values less than 0.01 and 0.001.*

FDA Label Image

Cockcroft And Gault Equation (Image 04)

An illustration showing the formula for calculating creatinine clearance (CLCr). The formula uses age, weight, serum creatinine, and a correction factor for female patients. This equation is commonly referenced in clinical pharmacology contexts.*

FDA Label Image

Gabapentin Structural Formula (Image 05)

Chemical structure of gabapentin shown as a molecular diagram with a cyclohexane ring, an amino group (CH2NH2), and a carboxyl group (CH2CO2H) attached.*

FDA Label Image

Image-09 (Image 09)

A scatter plot chart showing the difference percentage on the y-axis and daily dose in milligrams on the x-axis. The chart compares data points from three studies labeled Study a, Study b, and Study c, represented by different colored squares, across daily doses ranging approximately from 600 mg to 1800 mg.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.